跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 13,868 条关于
“PARP1 inhibitors”
全部
13,868
临床试验
6,436
药物
3,232
机构
8
资讯
4,192
去年
Saruparib Shows Promise as Selective PARP1 Inhibitor in Advanced Solid Tumors
去年
Rakovina Therapeutics Advances Novel AI-Discovered PARP1 and ATR Inhibitors for Hard-to-Treat Cancers
上个月
IMPACT Therapeutics Licenses PARP Inhibitor Senaparib to Pharmanovia in Deal Worth Up to €423.5 Million
去年
FDA-Approved PARP Inhibitor Shows 80% Tumor Reduction in EBV-Driven Lymphoma
去年
Duke Street Bio Receives EMA Approval for First-in-Human Trial of PARP1 Inhibitor DSB2455
2年前
Saruparib Shows Promise in HRR-Deficient Breast Cancer
去年
Duke Street Bio Receives FDA Fast Track Designation for Brain-Penetrating PARP1 Inhibitor DSB2455
9天前
1cBio Licenses Preclinical PARP1 Inhibitor OC-3 to Lee's Pharm for Greater China and Southeast Asia in Deal Worth Up to $27 Million
4个月前
CU Anschutz Cancer Center Leads Global Phase 3 Trial Testing Novel PARP Inhibitor Combination for BRCA-Mutated Metastatic Breast Cancer
9个月前
Trabectedin-Olaparib Combination Shows Promise for Advanced Soft Tissue Sarcoma Subgroups
第 1 页,共 420 页
上一页
下一页